Relay Therapeutics RLAY 深 沪
等待开盘 11-06 09:30:00 美东时间
17.00
-1.030
-5.71%
华盛通- 最 高18.205
- 今 开18.20
- 成交量 472.64万股
- 最 低 16.525
- 昨 收 18.03
- 总市值 37.25亿
- 52周最高 21.27
- 市盈率 静 --
- 换手率 2.16%
- 52周最低 6.17
- 委 比 36.91%
- 总股本 2.19亿
- 历史最高 64.37
- 量 比 1.54
- 振 幅 9.32%
- 历史最低 1.775
- 每 手 1
- 风险率 4.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Relay Therapeutics收涨3.38%，成交额6653.26万美元
11月5日，Relay Therapeutics（RLAY）收涨3.38%，报18.03美元，成交额6653.26万美元，市值39.51亿美元。 行情数据 •...
11-05 06:11
Relay Therapeutics Q3 EPS $(0.37) Beats $(0.40) Estimate
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.40) by 7.5 percent. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.
11-05 05:09
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics reported Q3 2026 financial results and updates, including the Phase 3 ReDiscover-2 trial for 2L breast cancer expected to complete enrollment mid-2027. Updated data from the ReInspire trial for zovegalisib in vascular anomalies will be presented at ASH 2026. Shannon Campbell was appointed to lead commercial preparations. The company announced a new mutant-selective TIE2 inhibitor program targeting vascular anomalies. Cash reser...
11-04 21:05
Relay Therapeutics收跌5.83%，成交额4998.95万美元
11月3日，Relay Therapeutics（RLAY）收跌5.83%，报17.28美元，成交额4998.95万美元，市值37.87亿美元。 行情数据 •...
11-03 06:11
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company developing therapies for cancer and genetic diseases, will release its third quarter 2026 financial results and corporate updates after U.S. markets close on November 4, 2026. The company's Dynamo® platform integrates computational and experimental approaches to target previously intractable proteins. Its lead asset, zovegalisib, is a Phase 3 pan-mutant PI3Kα inh...
10-28 20:12
Relay Therapeutics收跌0.33%，成交额2880.13万美元
10月27日，Relay Therapeutics（RLAY）收跌0.33%，报18.12美元，成交额2880.13万美元，市值39.71亿美元。 行情数据 ...
10-27 05:11
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics appoints Kristine Peterson and Lonnel Coats to its Board of Directors, adding extensive commercial and product launch experience ahead of the December 22 PDUFA target date for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both executives bring deep expertise in launching and commercializing therapies, particularly in cardiovascular and metabolic disease. Peterson, with over three decades in biopharma...
10-19 20:05
Relay Therapeutics收跌5.9%，成交额3898.18万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:15
Most shorted stocks on Wall Street
As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of...
10-05 21:35
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
